How Frontline Therapy Affects Sequencing Considerations in EGFR-Mutated NSCLC

Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, explore how initial treatment choice impacts subsequent sequencing strategies in EGFR-mutated NSCLC. Neal highlights resistance mechanisms that emerge after frontline targeted therapy and their implications for later-line options. Goldberg discusses the importance of repeat molecular testing and adapting therapy based on evolving tumor biology.